Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a rare form of chronic cutaneous lupus, lupus erythematosus profundus, was treated effectively with topical and systemic therapies, leading to improvement and healing of ulcerations, though resulting in atrophic scars and macules.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This case report describes an elderly man with erosive pustular dermatosis of the scalp, who improved with potent topical corticosteroids followed by maintenance with topical tacrolimus.

In this article, the authors detail their experience with AltrenoTM, a new topical retinoid lotion used for treating mild to moderate acne, reporting clinical effectiveness and satisfactory tolerability among patients of various ages, including children as young as 9.

This case series describes Erythromelanosis follicularis faciei et colli in five Indian patients, suggesting it may be more common than currently reported.

In this study of 35 patients with scalp alopecia areata, calcipotriol ointment led to faster and greater hair regrowth than clobetasol, though differences were not statistically significant.

This study found that patients with kerion responded well to antifungal treatments, with a lower dose of prednisolone effectively reducing inflammation when systemic corticosteroids were needed.

This study assessed the safety and efficacy of Romantaque lotion for unwanted hair growth and found statistically significant hair growth inhibition with no adverse effects in 30 volunteers after repeated applications over one year.

New therapy helps treat hair loss.

This study found that in mouse models, the novel NF-κB inhibitor DHMEQ improved symptoms of atopic dermatitis as effectively as tacrolimus or betamethasone.

This study highlights the potential of a ketoconazole antifungal hair spray as an innovative and effective topical method for treating tinea capitis, offering benefits such as easy application, improved drug penetration, and reduced systemic exposure compared to conventional treatments.

In this randomized control trial, researchers reported that topical calcipotriol was more effective than topical tacrolimus in promoting hair growth for patients with alopecia areata over a 6-month period, with a statistically significant difference in efficacy.

This study found that oral etretinate improved skin conditions like erythrodermic and pustular psoriasis, although less so for psoriasis vulgaris and lichen planus, with notable side effects including cheilitis and mucous membrane dryness.

This review reports that 100 mg/day spironolactone improved hair growth more than placebo and was more effective in reducing hair growth than finasteride and low-dose cyproterone acetate, but its effectiveness for acne remains unclear due to small sample sizes.

Topical tretinoin 0.025% cream is an effective treatment for Eruptive Vellus Hair Cysts in children.

The Exfoliate-Dissolve-Repair skincare approach may effectively treat keratosis pilaris and reduce the need for corticosteroids.

This article reviews the clinical presentation, diagnosis, and treatment options for discoid lupus erythematosus and reports no new clinical results.

This study observed that apremilast treatment improved skin lesions and reduced pruritus in patients with chronic, severe atopic dermatitis and one case of hand and foot dermatitis.

This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.

Using Excimer light with topical steroids is the most effective treatment for alopecia areata.

This study observed that oclacitinib, combined with oral glucocorticoids, achieved rapid and lasting clinical remission in four dogs with refractory juvenile-onset ischaemic dermatopathy, suggesting oclacitinib's potential as a useful immunosuppressive treatment in such cases.

In this study, an oleanolic acid-containing scalp treatment increased terminal hair counts significantly more than placebo in men under 50 with androgenic alopecia, but only three showed clinical improvement, with minimal side effects reported.

In this study, lysocellin induced G1 phase arrest in human osteosarcoma cells, but diminished the cytotoxic efficacy of etoposide, while its derivative alopestatin may reduce etoposide-induced alopecia in a rat model.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

This study found that both 2.5 mg/mL and 5 mg/mL concentrations of intralesional triamcinolone acetonide are effective for treating patchy alopecia areata, but the higher concentration promoted greater hair regrowth and density with more side effects.

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.

This systematic review of three randomized controlled trials found that topical eflornithine is an effective adjunctive therapy for reducing unwanted facial hair in women with hirsutism, with benefits lasting at least six months, although efficacy may diminish over time.

In this study, both topical clobetasol propionate and fractional Er: YAG laser followed by topical steroids demonstrated significant improvement in patients with alopecia areata, but the combined laser and steroid treatment was found to be more effective and safe.